Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper S Champiat, O Lambotte, E Barreau, R Belkhir, A Berdelou, F Carbonnel, ... Annals of Oncology 27 (4), 559-574, 2016 | 1009 | 2016 |
Anakinra for severe forms of COVID-19: a cohort study T Huet, H Beaussier, O Voisin, S Jouveshomme, G Dauriat, I Lazareth, ... The Lancet Rheumatology 2 (7), e393-e400, 2020 | 672 | 2020 |
Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension F Perros, D Montani, P Dorfmüller, I Durand-Gasselin, C Tcherakian, ... American journal of respiratory and critical care medicine 178 (1), 81-88, 2008 | 546 | 2008 |
Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome V Cottin, J Le Pavec, G Prévot, H Mal, M Humbert, G Simonneau, ... European respiratory journal 35 (1), 105-111, 2010 | 521 | 2010 |
Immunosuppressive therapy in lupus‐and mixed connective tissue disease–associated pulmonary arterial hypertension: a retrospective analysis of twenty‐three cases X Jais, D Launay, A Yaici, J Le Pavec, C Tchérakian, O Sitbon, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2008 | 436 | 2008 |
Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology D Montani, L Achouh, P Dorfmüller, J Le Pavec, B Sztrymf, C Tchérakian, ... Medicine 87 (4), 220-233, 2008 | 393 | 2008 |
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022 | 348 | 2022 |
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ... JAMA oncology 5 (9), 1310-1317, 2019 | 314 | 2019 |
Portopulmonary hypertension: survival and prognostic factors J Le Pavec, R Souza, P Herve, D Lebrec, L Savale, C Tcherakian, X Jaïs, ... American journal of respiratory and critical care medicine 178 (6), 637-643, 2008 | 283 | 2008 |
Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension A Campo, SC Mathai, J Le Pavec, AL Zaiman, LK Hummers, D Boyce, ... American journal of respiratory and critical care medicine 182 (2), 252-260, 2010 | 265 | 2010 |
Outcomes of hospitalisation for right heart failure in pulmonary arterial hypertension A Campo, SC Mathai, J Le Pavec, AL Zaiman, LK Hummers, D Boyce, ... European Respiratory Journal 38 (2), 359-367, 2011 | 210 | 2011 |
HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era B Degano, M Guillaume, L Savale, D Montani, X Jaïs, A Yaici, J Le Pavec, ... Aids 24 (1), 67-75, 2010 | 209 | 2010 |
Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases R Souza, M Humbert, B Sztrymf, X Jais, A Yaici, J Le Pavec, F Parent, ... European Respiratory Journal 31 (2), 343-348, 2008 | 172 | 2008 |
Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies J Le Pavec, G Lorillon, X Jaïs, C Tcherakian, S Feuillet, P Dorfmüller, ... Chest 142 (5), 1150-1157, 2012 | 159 | 2012 |
Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of … D Launay, O Sitbon, J Le Pavec, L Savale, C Tcherakian, A Yaïci, ... Rheumatology 49 (3), 490-500, 2010 | 157 | 2010 |
Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies J Le Pavec, RE Girgis, N Lechtzin, SC Mathai, D Launay, LK Hummers, ... Arthritis & Rheumatism 63 (8), 2456-2464, 2011 | 155 | 2011 |
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study D Montani, B Girerd, X Jaïs, M Levy, D Amar, L Savale, P Dorfmüller, ... The Lancet Respiratory Medicine 5 (2), 125-134, 2017 | 153 | 2017 |
Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension SC Mathai, M Bueso, LK Hummers, D Boyce, N Lechtzin, J Le Pavec, ... European Respiratory Journal 35 (1), 95-104, 2010 | 149 | 2010 |
Systemic sclerosis-associated pulmonary arterial hypertension J Le Pavec, M Humbert, L Mouthon, PM Hassoun American journal of respiratory and critical care medicine 181 (12), 1285-1293, 2010 | 142 | 2010 |
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension B Degano, A Yaïci, J Le Pavec, L Savale, X Jaïs, B Camara, M Humbert, ... European Respiratory Journal 33 (1), 92-98, 2009 | 130 | 2009 |